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Prions to Pathways:
Safeguarding Against Creutzfeldt-Jakob Disease in the Operating Room
Jessica Mary Adams Atkinson, BSN, RN and Sonja Carol Orff, MS, RN, CNL
Pathway Development and Implementation

Introduction
As defined by the Center for Disease Control (CDC, 2018), Creutzfeldt-Jakob Disease
(CJD) is a rapidly progressive, rare, transmissible, and fatal illness. Miscoiling of healthy
proteins caused by an abnormal isoform of cellular glycoprotein resulting in protein
folding has been found to be the molecular mechanism during the pathological process
of this malady (Figure 1), (Castle, Gill, 2017).
The current problem is that few recommendations are available for organizations to
consider how to manage potential CJD patient cases, and institutions are left to compile
and develop their own guidelines and/or protocols for clinical practice. The standards
of care for this rare disease in healthcare are evolving quickly and are often forged from
experiences (Thomas et. al. , 2013).
This poster displays a quality
improvement project and synthetizes the
process and experiences of how one
organization transformed and optimized
CJD prevention strategies. A pathway
was developed that enhances patient
identification, promotes multidirectional
coordination, utilizes communication
tools, and supports interprofessional
debriefings, resulting in harmonized CJD
Figure 1. Schematic representation of cellular prion protein
patient care.
(Legname, 2017).

The process started in November, 2016 to create prevention strategies and a policy for the
interprofessional stakeholders in a large tertiary care organization. Pathway development
was a multilayered shared process requiring extensive exploration and review of current
evidence to achieve consensus amongst stakeholders. The sequential efforts included
practice gap identification, decision making, and role clarification on how to standardize
care for the potential CJD population.

Literature Review
and
Expert Consultations

• The CDC and World Health Organization were consulted. They provided general guidelines and
recommendations for the management of the patient with CJD in the hospital organization.
• A comprehensive literature search and review was completed. The content of the current literature
focused primarily on the microbiological aspect of the disease, the transmission, the incidence, and the
fatality of CJD.
• Fifteen round table discussions were conducted with experts from Perioperative Leadership,
Neurology, Neurosurgery, Anesthesia, Pathology, Infection Prevention, Safety Management and Risk
Management. These meetings focused on risk screening and symptom identification.

Patient
Identification

• Agreed screening criteria: any patient with symptoms of rapidly progressive dementia, ataxia,
encephalopathy or neuropsychological symptoms without clear etiology will be identified as a risk for
CJD.
• Testing: at risk patients will undergo further testing and have a lumbar puncture screening for 14-3-3
protein. If positive, a non-directed brain biopsy will follow. If negative, additional testing needs to be
considered.
• Operating Room: any patient with rapidly progressing neurological symptoms and undergoing
non-directed brain biopsy will be treated under the high infectivity prion protocol.

Multidirectional
Coordination

• Roles, responsibilities, and patient flow coordination: the Surgeon in collaboration with the
Neurologist and provider caring for the patient, who have identified a patient at risk for prion disease,
will determine and coordinate the most appropriate location for testing.
• Once the proceduralist and the appropriate location have been determined, Infection Prevention (IP)
is notified of the proposed surgery/procedure. IP then deploys communication to affected
departments in preparation for procedure.
• Timeline: no less than 24 hours is given to allow for involved departments and teams to coordinate
preparations to conduct procedure.

Outcome
This topic magnified the institutional vulnerability and safety risks inherent to a disease that
is high risk, low volume, and with limited availability of guidelines. The outcome of the
process was an institutional policy describing the identification and management of patients
with concerns for CJD. This policy extends to, but is not limited to, the perioperative area,
interventional radiology, and the patient bedside. The provider is enabled with an
interprofessional team to safely deliver evidence-based care for a patient whose neurological
diagnosis is unclear. This work has introduced and discussed an approach that is replicable
in other organizations that may consider developing a pathway and policy, in anticipation
and preparation for managing patients who may undergo the undirected brain biopsy.
Implications for Perioperative Care

The estimated occurrence of CJD worldwide and in the United States has been reported to
affect approximately 1:1,000,000 people per year (CDC, 2018). The prevalence of CJD can
be anticipated to increase (Figure 3). The signs and symptoms of the disease are deceptive
and brain biopsy is used to support conclusive diagnosis. Increased awareness and
proactivity, as indicated also by AORN, will safeguard the OR environment, staff, patients
and families, and the institution against this insidious disease (Anderson, 2018). Our
recommendation is that every institution considers a policy and a pathway that provides
guidance to the interprofessional team clarifying expectations, roles and responsibilities, and
offering tools for managing patients with concerns for CJD. Together, this work serves to
prepare for a one in one million opportunity.

Approach
The potential presence of CJD in the perioperative patient requires interprofessional
care and team collaboration because the signs and symptoms of this disease can be
misleading. This includes not just perioperative staff, but also experts representing
Neurology, Neurosurgery, Anesthesia, Pathology, Infection Prevention, and Safety
Management, amongst others. Inpatient care teams, the patient, and families are also
essential partners for collaboration.

Communication
Tools

• Policy: is readily and electronically available for all departments and stakeholders.
• Huddle: pre-procedure huddle in the OR is crucial and called upon by the sponsor of the policy. This
huddle includes: Neurosurgeon, Anesthesiologist, Circulating RN, Surgical Technologist, and support
staff. The policy is reviewed and roles and responsibilities are clearly assigned.
• Additional communication tool: red Protocol Stop Signs are placed on all OR entrances and exits
where the procedure will be performed.

Figure 3. Creutzfeldt-Jakob Disease Deaths and Age-Adjusted Death Rate, United States, 1979-2016
(Centers for Disease Control and Prevention, 2018).
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Figure 2. Causes and consequences of CJD (World Health Organization, Centers for Disease Control and Prevention,
National Institute of Neurological Disorders and Stroke, AP).

For a patient, the symptoms of CJD are demonstrated by increasing memory
impairment that progresses to dementia and the disease is always fatal usually within
one year of onset of illness (Figure 2).

Interprofessional
Debriefings

• Debriefing: is organized by the policy sponsor after the procedure. This is designed as a structured
process and the goal is to analyze the implementation of the procedure whilst adhering to the policy.
The focused discussion provides the interprofessional team an opportunity to enhance performance,
optimize future procedures, identify communication breakdowns, and also highlight implementation
success.
• Documentation: content of the discussion is electronically recorded and available for the leadership
team of the organization.
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